NEW YORK (360Dx) – Bio-Techne announced after the close of the market on Monday that it has reached an agreement to acquire Exosome Diagnostics for up to $575 million.
Under the terms of the deal, expected to close in July or early August, Bio-Techne will pay $250 million in cash up front, and up to an additional $325 million contingent on the achievement of certain future milestones. The company said it will finance the deal through a combination of cash on hand and a revolving line of credit facility it anticipates obtaining prior to the closing of the deal.